Bicycle Therapeutics plc - ADR (BCYC)
NASDAQ
Delayed Data
Oct 21, 2026, 01:30 PM
Day's Range
3.5652 wk Range
3.33Overview - BCYC - Bicycle Therapeutics plc - ADR
Key Statistics
Valuation
Enterprise Value
-223.11M
P/E (Trailing)
-1.20
P/E (Forward)
-1.74
PEG Ratio
0.03
Price / Sales (TTM)
4.44
Price / Book
0.53
EV / EBITDA
1.11
Profitability
Profit Margin
0.00%
Operating Margin
-8,673.92%
Return on Assets
-17.90%
Return on Equity
-32.29%
Ownership
Shares Outstanding
69.81M
Float
7.75M
Short % of Shares Outstanding
8.46%
Held by Insiders
4.40%
Held by Institutions
71.90%
Price stats
Beta
1.68
50-Day Avg
3.95
200-Day Avg
4.80
Analyst Consensus
9 analysts
Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - BCYC - Bicycle Therapeutics plc - ADR
Peers - BCYC - Bicycle Therapeutics plc - ADR
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- BCYCNASDAQBicycle Therapeutics plc - ADR265.97MMarket Cap-107.89%52-week change-1.21P/E (Trailing)0.00%Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)32.26%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - BCYC - Bicycle Therapeutics plc - ADR
About
Bicycle Therapeutics plc - ADR is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycle molecules. The company applies its proprietary bicyclic peptide platform to create targeted therapies designed to address diseases that are underserved by existing treatments,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
